Загрузка...
A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not...
Сохранить в:
| Опубликовано в: : | Clin Nephrol Case Stud |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dustri-Verlag Dr. Karl Feistle
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5715206/ https://ncbi.nlm.nih.gov/pubmed/29318105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/CNCS109165 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|